Abstract
Women that are positive for an ovarian abnormality in a clinical setting can have either a malignancy or a benign tumor with probability favoring the benign alternative. Accelerating the abnormality to surgery will result in a high number of unnecessary procedures that will place cost burdens on the individual and the health delivery system. Surveillance using serial ultrasonography is a reasonable alternative that can be used to discover if changes in the ovarian abnormality will occur that favor either a malignant or benign interpretation. Several ovarian cancer screening trials have had extensive experiences with changes in subclinical ovarian abnormalities in normal women that can define growth, stability or resolution and give some idea of the time frame over which changes occur. The present report examines these experiences and relates them to the current understanding of ovarian cancer ontology, presenting arguments related to the benefits of surveillance.
Document Type
Review
Publication Date
4-28-2017
Digital Object Identifier (DOI)
https://doi.org/10.3390/diagnostics7020025
Repository Citation
Ormsby, Eleanor L.; Pavlik, Edward J.; and McGahan, John P., "Ultrasound Monitoring of Extant Adnexal Masses in the Era of Type 1 and Type 2 Ovarian Cancers: Lessons Learned From Ovarian Cancer Screening Trials" (2017). Obstetrics and Gynecology Faculty Publications. 18.
https://uknowledge.uky.edu/obgyn_facpub/18
Included in
Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Obstetrics and Gynecology Commons
Notes/Citation Information
Published in Diagnostics, v. 7, issue 2, 25, p. 1-19.
© 2017 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).